

26 April 2018

FIRST QUARTER CHINA SALES PROGRESS

EVE Investments (ASX:EVE), an ASX-listed technology investment company, is pleased to provide an update on Omni Innovation, a medical technology company focused on medical nutrition and in which EVE has a 38% interest, has a licence agreement in place with Eagle Health for the manufacture and distribution of its pre-meal drink for people with Type 2 diabetes and pre-diabetes.

EVE Investments notes that Eagle Health have today released the following information regarding the first quarter performance of Hutang-1. Hutang-1 is the name of the pre-meal drink in the Chinese market.

Hutang-1, has now reached over 80,000 consumers, including over 24,000 diabetes or pre-diabetes patients and showed promising conversion to sales. This commercial roll-out is being conducted with four dedicated retail stores in Xiamen and a direct community outreach program. Eagle Health are scaling up more specialty stores beyond Xiamen and into other Chinese regions in quarter 2, and expect the trend in traffic and sales conversion to further increase.

Managing Director of Eagle Health, Mr Zhang Mingwang, commenting on the first quarter performance of Hutang-1:

“Given our ongoing roll-out of the Hutang-1 diabetes product, we remain dedicated and committed to helping educate the wider community about diabetes management. The clinically proven diabetes pre-meal shake developed and tested in Australia is the first of its kind to be made available to patients in this category. According to the International Diabetes Federation, China has 114.4 million people with diabetes and this large scale and developing trend has been reflected in the customer and conversion numbers we have seen in just four of our dedicated diabetes outlets in Xiamen.”

About EVE Investments

EVE Investments is an Australian Securities Exchange Listed Investment Company that invests in medical nutrition companies. EVE is an investment partner that wants to help build ground breaking and enduring technology with a preference for companies that have global scale.

For more information, please visit www.eveinvestments.com.au and follow us on Twitter @EVEInvestments

For more information:

Ben Rohr

Investment Director

+61 8 6465 5500

benr@eveinvestments.com.au